<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363034</url>
  </required_header>
  <id_info>
    <org_study_id>260944</org_study_id>
    <nct_id>NCT04363034</nct_id>
  </id_info>
  <brief_title>Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program</brief_title>
  <official_title>Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <brief_summary>
    <textblock>
      This is an expanded access treatment protocol to treat up to 100 patients with severe or&#xD;
      life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an expanded access treatment protocol to treat up to 100 subjects with severe or&#xD;
      life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma. Subjects&#xD;
      will receive 1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible,&#xD;
      low isohemagglutinin titer, COVID-19 convalescent plasma. Plasma will be administered one&#xD;
      unit per day for up to two days. The duration of infusion will usually take 1 to 2 hours&#xD;
      (rate of 100 to 250 mL/hr). The infusion should not exceed 4 hours. Plasma infusions will be&#xD;
      administered following standard institutional procedures, including the use of premedications&#xD;
      (e.g. acetaminophen, diphenhydramine, etc.) as necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>COVID-19</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible, low isohemagglutinin titer, COVID-19 convalescent plasma</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Laboratory confirmed COVID-19 via SARS-CoV-2 RT-PCR testing&#xD;
&#xD;
          -  Patients currently hospitalized with severe or life-threatening COVID-19 or patients&#xD;
             the treating physician deems to be at high-risk for progressing to severe or&#xD;
             life-threatening COVID-19.&#xD;
&#xD;
               -  Severe disease, defined as one or more of the following:&#xD;
&#xD;
                    -  dyspnea,&#xD;
&#xD;
                    -  respiratory frequency ≥ 30/min,&#xD;
&#xD;
                    -  blood oxygen saturation ≤ 93%,&#xD;
&#xD;
                    -  partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt;&#xD;
                       300, and/or&#xD;
&#xD;
                    -  lung infiltrates &gt; 50% within 24 to 48 hours&#xD;
&#xD;
               -  Life-threatening disease, defined as one or more of the following:&#xD;
&#xD;
                    -  respiratory failure,&#xD;
&#xD;
                    -  septic shock, and/or&#xD;
&#xD;
                    -  multiple organ dysfunction or failure&#xD;
&#xD;
          -  Patients or their legally authorized representative must provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients with positive pregnancy test, breastfeeding, or planning to become&#xD;
             pregnant/breastfeed during the study period.&#xD;
&#xD;
          -  Patients who have received pooled immunoglobulin in past 30 days&#xD;
&#xD;
          -  Contraindication to transfusions or history of prior reactions to transfusion blood&#xD;
             products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Danielle Evans</last_name>
    <phone>(501) 526-7906</phone>
    <email>DEvans@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Avery</last_name>
    <phone>(501) 214-2101</phone>
    <email>daavery@uams.edu</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

